常见炎症性疾病生物制剂治疗患者的黑色素瘤风险:系统综述与荟萃分析
该系统综述与荟萃分析检索Embase、MEDLINE和CENTRAL(1995年1月1日至2019年2月7日),纳入7项队列研究,共34 029例生物制剂治疗患者和135 370例未使用生物制剂、接受传统系统治疗的患者。结果显示,生物制剂治疗与炎症性肠病、类风湿关节炎和银屑病患者的黑色素瘤风险呈正相关,但差异均无统计学意义。作者认为,基于当前证据不能排除临床重要的黑色素瘤风险升高,仍需大样本并校正关键危险因素的研究。
要点
- 生物制剂治疗者黑色素瘤风险呈正相关但均无统计学意义。
- 炎症性肠病pRR 1.20(95%CI 0.60-2.40),类风湿关节炎pRR 1.20(95%CI 0.83-1.74)。
- 银屑病风险比1.57(95%CI 0.61-4.09),多数研究未校正其他危险因素。
核心结论
- 基于当前证据,不能排除常见炎症性疾病患者接受生物制剂治疗后黑色素瘤风险出现临床重要升高。
- 仍需大样本并校正关键危险因素的研究来解决生物制剂长期安全性问题。
研究设计与样本
- 系统综述与荟萃分析,检索Embase、MEDLINE和CENTRAL,发表时间1995年1月1日至2019年2月7日。
- 纳入随机临床试验、队列研究和巢式病例对照研究,比较生物制剂与传统系统治疗者的黑色素瘤风险。
- 共纳入7项队列研究,含34 029例生物制剂治疗患者和135 370例未使用生物制剂、接受传统系统治疗的患者。
- 由两名评价者独立提取资料,合并风险估计值,采用随机效应与固定效应模型,并用I2统计量评估异质性,遵循MOOSE报告规范。
主要发现
- 炎症性肠病患者中,生物制剂治疗与黑色素瘤呈正相关(pRR 1.20;95%CI 0.60-2.40),差异无统计学意义。
- 类风湿关节炎患者中,生物制剂治疗与黑色素瘤呈正相关(pRR 1.20;95%CI 0.83-1.74),差异无统计学意义。
- 银屑病患者中,生物制剂治疗与黑色素瘤呈正相关(风险比1.57;95%CI 0.61-4.09),差异无统计学意义。
- 多数研究未对其他危险因素进行校正。
关键数值与推荐
- 主要结局为生物制剂治疗患者与未使用生物制剂、接受传统系统治疗患者相比的黑色素瘤合并相对风险(pRR)。
- 炎症性肠病pRR 1.20(95%CI 0.60-2.40);类风湿关节炎pRR 1.20(95%CI 0.83-1.74);银屑病风险比1.57(95%CI 0.61-4.09)。
临床怎么用
- 对炎症性肠病、类风湿关节炎和银屑病患者启动生物制剂治疗前,应评估黑色素瘤危险因素。
- 治疗期间应重视皮肤监测,但现有证据尚不足以量化生物制剂相关的黑色素瘤风险升高幅度。
局限性
- 多数纳入研究未校正其他危险因素。
- 银屑病相关结果仅基于风险比,且置信区间较宽。
- 作者指出需大样本并校正关键危险因素的研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Biologic therapies are widely prescribed immunomodulatory agents. There are concerns that compared with treatment with conventional systemic therapy, long-term biologic treatment for common immune-mediated inflammatory diseases, namely inflammatory bowel disease (IBD), rheumatoid arthritis (RA), and psoriasis, may be associated with increased risk of melanoma. OBJECTIVE: To examine whether biologic treatment of IBD, RA, or psoriasis is associated with an increased risk of melanoma compared with conventional systemic therapy. DATA SOURCES: Embase, MEDLINE, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched for articles published from January 1, 1995, to February 7, 2019, for eligible studies. STUDY SELECTION: Randomized clinical trials, cohort studies, and nested case-control studies quantifying the risk of melanoma in biologic-treated patients with IBD, RA, and psoriasis compared with patients treated with conventional systemic therapy were included. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted key study characteristics and outcomes. Study-specific risk estimates were pooled, and random- and fixed-effects model meta-analyses were conducted. Heterogeneity was assessed using the I2 statistic. The Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines were followed. MAIN OUTCOMES AND MEASURES: The pooled relative risk (pRR) of melanoma in biologic-treated patients with IBD, RA, and psoriasis compared with biologic-naive patients treated with conventional systemic therapy. RESULTS: Seven cohort studies comprising 34 029 biologic-treated patients and 135 370 biologic-naive patients treated with conventional systemic therapy were eligible for inclusion. Biologic treatment was positively associated with melanoma in patients with IBD (pRR, 1.20; 95% CI, 0.60-2.40), RA (pRR, 1.20; 95% CI, 0.83-1.74), or psoriasis (hazard ratio, 1.57; 95% CI, 0.61-4.09) compared with those who received conventional systemic therapy, but the differences were not statistically significant. Adjustment for other risk factors was absent from most studies. CONCLUSIONS AND RELEVANCE: The findings suggest that clinically important increases in melanoma risk in patients treated with biologic therapy for common inflammatory diseases cannot be ruled out based on current evidence. However, further studies with large patient numbers that adjust for key risk factors are needed to resolve the issue of long-term safety of biologic therapy.
引用
- Esse S, Mason KJ, Green AC, et al. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis. JAMA Dermatol. 2020. PMID: 32432649. doi:10.1001/jamadermatol.2020.1300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。